Thyro-Tabs® Canine achieves FDA approval.

• It is now the first and only FDA approved canine T4 tablet brand.

• Many are not aware that all other Canine T4 tablet brands currently prescribed in the U.S. are not FDA approved.

• Plus Thyro-Tabs® Canine is now the first and only canine T4 tablet formulation designed to achieve the Higher USP tablet Standard.

Now all hypothyroid dogs can be prescribed the only Higher Standard T4 Tablet that is also FDA approved.

Thyro-Tabs® Canine (levothyroxine sodium tablets), USP

Call your distributor – ask for the only FDA Approved Canine T4 Brand.
Achieves FDA Approval
NADA #141-448

Thyro-Tabs® Canine
The ONLY Canine T4 Tablet Brand that Meets the Higher USP Standard

Levothyroxine sodium tablets are inherently unstable. Light, humidity, and oxygen exposure can result in dose potency degradation and sub-optimal treatment. In 2009, the United States Pharmacopeia (USP) published new potency requirements for levothyroxine sodium tablets. The more stringent standards challenged manufacturers to improve their manufacturing and packaging procedures in order to meet these aggressive performance targets. To date, only LLOYD, Inc. has achieved this goal for the veterinary market. Thyro-Tabs® Canine (levothyroxine sodium tablets), USP is the only veterinary brand to retain the USP tablet designation by providing 95% - 105% dose potency throughout the indicated shelf life. As such, the ability to manufacture to this higher standard was a contributing component in Thyro-Tabs® Canine receiving the first and only FDA approval for veterinary levothyroxine sodium tablets.

The Trouble with Levothyroxine

Formulation Stability
Levothyroxine sodium [O-(4-hydroxy-3,5-diiodophenyl) -3,5-diiodo-L-tyrosine, monosodium salt, hydrate] medications are notoriously unstable. As reported in numerous scientific publications, levothyroxine sodium tablets are highly susceptible to degradation caused by environmental factors, including light, humidity, and oxygen. Moreover, the resultant drug degradation leads to potency erosion, dose variability, and sub-optimal clinical response.

Historically, levothyroxine tablets were manufactured with a broad potency tolerance, with a potential dose differential between newly manufactured tablets and those approaching expiration as great as 20%. Such dose variability clearly impedes achievement of therapeutically ideal T4 levels.

Canine Challenges
In addition to the inherent instability of levothyroxine sodium medications, canine patients are challenged with poor bioavailability (10%-22%) and highly variable drug absorption. Although the reasons are not fully understood, studies have reported as much as a 4-fold difference in peak concentration values among dogs receiving the same dose.

Within a dog population, the physiological characteristics of an individual dog are the most significant determinant of achievable serum T4 concentrations. Another primary factor influencing levothyroxine absorption is food. Giving levothyroxine with a meal decreases the absorption by 50%. Because of the poor bioavailability and variable absorption, it is important to maintain a consistent dosing regimen for hypothyroid dogs. One key to achieving consistent serum T4 concentrations and more predictable clinical responses is reliable dose potency.

The United States Pharmacopeia (USP)
The USP is an independent, non-profit, scientific organization officially recognized by the Food and Drug Administration (FDA) as the accepted authority for defining pharmaceutical standards of purity, potency, and formulation characteristics.
A New Potency Standard

Prior to October 2009, the USP specification for levothyroxine sodium tablets required 90% - 110% dose potency throughout the indicated shelf life. In October 2009, in response to an FDA petition, the potency specification was tightened from a minimum of 95% to a maximum of 105% of the indicated dose. The source (October 2007) FDA petition to improve dose reliability was based on the recommendation of the Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Advisory Committee for Pharmaceutical Science held on 4 October 2006.

No other canine T4 tablets meet the higher USP standard OR are FDA approved

From FDA (CVM) website: “A number of other levothyroxine sodium products are currently marketed in the U.S. for use in dogs; however, none are FDA-approved. In January 2016, FDA issued warning letters to companies manufacturing an unapproved levothyroxine product informing them that they are in violation of the law.”

Thyro-Tabs® Canine (levothyroxine sodium tablets), USP (LLOYD, Inc., Shenandoah, Iowa) is the unique exception.

Achieving the New Standard

Controlling exposure and vulnerability to light, humidity, and oxygen are critical for maintaining stable, long-term levothyroxine sodium tablet potency. After more than eight years of extensive research and development work, LLOYD, Inc. has defined a highly specialized formulation and product containment system to achieve this goal. Through proprietary systems and techniques, advanced formula Thyro-Tabs® Canine is the only veterinary brand to guarantee a minimum 95% dose potency for a full 24 months from date of manufacture. In fact, Thyro-Tabs® Canine is the sole hypothyroid medication for dogs that is manufactured under identical conditions and standards as Thyro-Tabs® for the human market (NDA 21-116).

New BEST Practice for Sustainable Potency

Although the only way to assure absolute levothyroxine sodium tablet dose stability is to completely avoid exposure to light, humidity, and oxygen, ultimately, this is not possible. Therefore the best practice for dispensing levothyroxine sodium tablets requires minimized tablet degradation risk wherever possible. LLOYD has developed a dispense-ready 120-count bottle with an advanced closure system that specifically addresses long-term stability and potency control. This direct-dispense container system dramatically reduces in-clinic degradation risk by eliminating the need for repeated in-clinic open and count procedures. Additionally, the protective closure mechanism continues to provide added protection throughout the client use timeline.

The issue of levothyroxine sodium tablet instability, although long recognized, has only recently been addressed through tighter regulatory specifications. The new USP/FDA requirements challenged manufacturers to invest in finding solutions—for consistent dose potency and more reliable therapeutic outcomes.

LLOYD, Inc. has taken the lead in this effort. Through dedicated research, we have optimized the Thyro-Tabs® Canine formulation and packaging so veterinary practitioners and pet owners alike can feel confident that every tablet is providing the correct dose, and the proper endocrinologic support.

W. Eugene Lloyd, DVM, PhD, DABVT
Carla M.K. Morrow, DVM, PhD, DABVT
Pre-2009 USP/FDA standards mandated a minimum 90% potency standard for levothyroxine sodium medications. Such a wide tolerance risks a significant level of sub-optimal therapy for hypothyroid dogs. Thyro-Tabs® Canine is the first and only canine T4 tablet to meet the new higher USP/FDA potency standard of 95%-105%. Plus only Thyro-Tabs® Canine provides 24 months real-time tablet dose stability.5

FDA Approved Higher Tablet Standard

In light of low canine bioavailability and high absorption variability among individual dogs, reliable dose potency becomes an essential tool toward successful therapy. Thyro-Tabs® Canine is the only levothyroxine sodium tablet to provide a 24 month minimum 95% tablet dose potency guarantee, as recognized by the USP. As such, Thyro-Tabs® Canine obtained FDA approval in the treatment of diminished thyroid function in dogs (canine hypothyroidism).

References
4. http://www.fda.gov/AnimalVeterinary/SafetyHealth/ProductSafetyInformation/ucm482116.htm
5. From Date of Manufacture at 95% - 105% Tablet, USP standard.